Lorcaserine in combination with XR-Naltrexone for relapse prevention opioid use disorder
Medication trial for the treatment of opiate use disorder
Sponsor: NIDA
Enrolling: Male and Female Patients
Study Length: 8 Weeks
Clinic Visits: 20
IRB Number: 7501
U.S. Govt. ID: NCT03169816
Contact: Daniel Brooks: 212-923-3031 / daniel.brooks@nyspi.columbia.edu
Additional Study Information: This study proposes to recruit patients with Opioid Use Disorder (OUD) seeking treatment into our program of a 5 day outpatient detoxification and naltrexone induction followed by a relapse-prevention treatment with Extended release-naltrexone (XR-NTX) for 8 weeks.
This study is closed
Frances Levin, MD
Do You Qualify?
Have you been using opiates or heroin for at least 6 months? Yes No
Are you seeking to stop using opiates or heroin? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Daniel Brooks